Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model.
Cannabinoid CB(2) Receptor (CB(2)) activation has been shown to have immunomodulatory properties without psychotropic effects. The hypothesis of this study is that selective CB(2) agonist treatment can attenuate cerebral ischemia/reperfusion injury. Selective CB(2) agonists (O-3853, O-1966) were administered intravenously 1 h before transient middle cerebral artery occlusion (MCAO) or 10 mins after reperfusion in male mice. Leukocyte/endothelial interactions were evaluated before MCAO, 1 h after MCAO, and 24 h after MCAO via a closed cranial window. Cerebral infarct volume and motor function were determined 24 h after MCAO. Administration of the selective CB(2) agonists significantly decreased cerebral infarction (30%) and improved motor function (P<0.05) after 1 h MCAO followed by 23 h reperfusion in mice. Transient ischemia in untreated animals was associated with a significant increase in leukocyte rolling and adhesion on both venules and arterioles (P<0.05), whereas the enhanced rolling and adhesion were attenuated by both selective CB(2) agonists administered either at 1 h before or after MCAO (P<0.05). CB(2) activation is associated with a reduction in white blood cell rolling and adhesion along cerebral vascular endothelial cells, a reduction in infarct size, and improved motor function after transient focal ischemia.
Zhang
Ming
M
Department of Physiology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
Martin
Billy R
BR
Adler
Martin W
MW
Razdan
Raj K
RK
Jallo
Jack I
JI
Tuma
Ronald F
RF
D000818:Animals; D001921:Brain / Q000098:blood supply / Q000378:metabolism / Q000503:physiopathology; D002448:Cell Adhesion / Q000276:immunology; D002544:Cerebral Infarction / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000276:immunology / Q000378:metabolism; D036904:Leukocyte Rolling / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018696:Neuroprotective Agents / Q000494:pharmacology*; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000378:metabolism*; D015427:Reperfusion Injury / Q000276:immunology / Q000378:metabolism* / Q000503:physiopathology
D018696:Neuroprotective Agents; D043885:Receptor, Cannabinoid, CB2